Sequence Inc. Opens New Training Facility!

Read the full press release
All Projects

Program Covington: Process Automation & Functional Requirement Specifications

Blood Plasma Therapeutics


Shire (now part of Takeda) built a 100-acre greenfield campus in Covington, Georgia. The campus includes over 1.0 million square feet of building space that was built to manufacture human plasma-derived drug substances and dosage form products. The site includes facilities for plasma testing, fractionation, formulation and filling, packaging, warehousing, central utilities, administration, and laboratory facilities.

Sequence Scope: Functional Requirement Specifications

This project included development of functional requirement specifications to define general and sequential functionality of the facilities, utilities, and process equipment per ISA-S88 standards to commercially manufacture blood plasma derived therapeutics on a DeltaV DCS platform with ~17,500 I/O.

Utilities included: WFI, RO, Compressed Air, Clean Steam, Alcohol, etc.)

Process Equipment included: Ultrafiltration/Diafiltration, Centrifuges, Filtration, Chromatography Skids, Buffer Preparation and associated CIP

Life Impact

  • The Takeda state-of-the-art facility is providing much needed additional capacity for meeting increasing global demand for plasma-derived therapies. Ig is a critical treatment for primary immunodeficiency (PI) diseases in which part of the body immune system is missing or functions incorrectly.

  • Manufactured drugs include FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis), cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN), Immuno Globulin. Source

Get Started

How can Sequence support your project success?

Contact Us
  • Sequence, Inc. Global Headquarters
    1400 Perimeter Park Drive
    Morrisville, NC 27560

  • Northeast Office
    1 Speen Street, Suite 120
    Framingham, MA 01701

Sign up for our email newsletter
white sequence logo

Accelerating time to market through proven quality and compliance solutions.

© 2023 Sequence, Inc. All rights reserved.